Professor of Neurosciences
Department of Biomedical Sciences, Faculty of Medicine and Health Sciences
Prof Guillemin’s team is one of the world’s leading research groups studying neuroactive (toxic or protective or immunomodulator) metabolites deriving from tryptophan metabolism and their involvement in several neurodegenerative diseases. Over the last two decades, he demonstrated the importance of this pathway in multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis, which has opened numerous new promising research avenues and has translated to important new prognostic and therapeutic strategies. Through their important international and national collaborative network, Prof Guillemin and his research team have extended their research to other diseases such as Parkinson’s disease, suicide, depression, autism, schizophrenia breast cancers and brain tumours.
BSc (Hon I), PhD
- Involvement of the kynurenine pathway in neurodegenerative diseases;
- Identification of biomarker for progression, severity and response to treatment for neurodegenerative diseases;
- Development of the new therapeutic strategies targeting the kynurenine pathway for neurodegenerative diseases and cancers;
- Identification of environmental factors associated with sporadic motor neuron disease (biotoxins and chemicals).
- Natural products and neuroprotection
- Understanding the role of the kynurenine pathway in human breast cancer immunobiology.. Heng B, Lim CK, Lovejoy DB, Bessede A, Gluch L, Guillemin GJ. Oncotarget. 2016 Feb 9;7(6):6506-20.
- Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers. Puccetti P, Fallarino F, Italiano A, Soubeyran I, MacGrogan G, Debled M, Velasco V, Bodet D, Eimer S, Veldhoen M, Prendergast GC, Platten M, Bessede A, Guillemin GJ. PLoS One. 2015 Apr 16;10(4):e0122046.
- Kynurenine-3-monooxygenase: a review of structure, mechanism, and inhibitors. Smith JR, Jamie JF, Guillemin GJ. Drug Discov Today. 2016 Feb;21(2):315-24.
- Altered kynurenine pathway metabolism in autism: Implication for immune-induced glutamatergic activity. Lim CK, Essa MM, de Paula Martins R, Lovejoy DB, Bilgin AA, Waly MI, Al-Farsi YM, Al-Sharbati M, Al-Shaffae MA, Guillemin GJ. Autism Res. 2015 Oct 24. doi: 10.1002/aur.1565.
- Long-term dietary supplementation of pomegranates, figs and dates alleviate neuroinflammation in a transgenic mouse model of Alzheimer's disease. Essa MM, Subash S, Akbar M, Al-Adawi S, Guillemin GJ. PLoS One. 2015 Mar 25;10(3):e0120964.
- Involvement of the kynurenine pathway in human glioma pathophysiology. Adams S, Teo C, McDonald KL, Zinger A, Bustamante S, Lim CK, Sundaram G, Braidy N, Brew BJ,Guillemin GJ. PLoS One. 2014 Nov 21;9(11):e112945.
- The potential for transition metal-mediated neurodegeneration in amyotrophic lateral sclerosis. Lovejoy DB, Guillemin GJ. Front Aging Neurosci. 2014 Jul 23;6:173.
- Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, Bicciato S, Mazza EM, Macchiarulo A, Vacca C, Belladonna ML, Orabona C, Bianchi R, Lanz TV, Platten M, Della Fazia MA, Piobbico D, Guillemin GJ, Prendergast GC, Metz R, Geffard M, Boon L, Pirro M, Iorio A, Veyret B, Romani L, Grohmann U, Fallarino F, Puccetti P. Nature. 2014 Jul 10;511(7508):184-90.
- Serum nicotinamide adenine dinucleotide levels through disease course in multiple sclerosis. Braidy N, Lim CK, Grant R, Brew BJ, Guillemin GJ. Brain Res. 2013 Nov 6;1537:267-72.
- Quinolinic acid: neurotoxicity. Guillemin GJ. FEBS J. 2012 Apr;279(8):1355.
Recent Grant Success
2015-2020:ARC discovery grant. “Biomagnification of BMAA in the environment: development of new detection tools, determination of exposure routes and neurotoxic mechanisms” CIA – Gilles Guillemin - $650,000
2016 : Motor Neuron Disease
Research Australia (MNDRIA) New
directions for early diagnosis of MND: a large-scale longitudinal analysis of
multiple biomarkers to find diagnostic and prognostic “fingerprints”.
CIA – Gilles Guillemin - $250,000
2016 : Motor Neuron Disease
Research Australia (MNDRIA) Identification of environmental risk factors for sporadic motor neurone
disease in Australia
CIB – Gilles Guillemin (au$100,000)
2016 : Motor Neuron Disease Research Australia (MNDRIA)
approaches to plasma biomarker studies in MND/ALS
CIC – Gilles Guillemin (au$100,000)
2016-2020 :NHMRC Dementia grant.“Developing insight into
the molecular origins of familial and sporadic frontotemporal dementia and
amyotrophic lateral sclerosis”
CID – Gilles Guillemin - $6,200,000
2016-2017 :Alzheimer Drug Discovery Foundation (ADDF) Research Grant (au$207,000) (2 year: 2016-17) “Neuroinflammation in frontotemporal dementia: the role of microglia in TDP-43-related disease” CIB – Gilles Guillemin.
2015-2016 :Alzheimer Drug Discovery Foundation (ADDF) Research Grant (au$198,000) “New inhibitors of kynurenine3 monooxygenase for Alzheimer’s disease therapy” CIA – Gilles Guillemin
2015 Cancer Institute NSW equipment grant
Platform for cancer drug monitoring and metabolite analysis supporting clinical and scientific cancer research CIE – Gilles Guillemin - $660,000